摘要
目的探讨不同剂量瑞舒伐他汀对Ⅲ度房室传导阻滞双腔起搏器治疗患者NT—proBNP及心脏重构的影响。方法选取2011年12月至2012年8月于我院心血管内科因Ⅲ度房室传导阻滞（AVB）住院并行双腔起搏器（DDD）治疗的患者60例，随机分为对照组、可定5mg组及可定10mg组各20例。分别测定术前、术后12个月三组患者NT—proBNP水平、左房内径（LA）、左室舒张末内径（LVEDD）、左室收缩末内径（LVESD）及左心室射血分数（LVEF）。结果三组患者治疗前NT—proBNP、LA、LVEDD、LVESD、LVEF差异无统计学意义（P〉0．05）。治疗后起搏器组及可定10mg组患者血浆NT—proBNP水平较治疗前下降（P=0．045，P〈0．01），可定10嗽组较单纯起搏器组下降更明显，差异有统计学意义（P=0．013）。治疗后三组患者LVEDD均较术前减小，且随可定用量增加减小更明显。治疗后可定5哗组LVESD较术前减小（P〈0．01），LVEF明显增高（P=0．032）；治疗后可定10mg组LA、LVESD较术前减小（P均〈0．01），LVEF明显增高（P=0．017）。治疗后可定5mg组及可定10mg组LA较起搏器组明显减小（P=0．048，P=0．043），LVESD减小，差异有统计学意义（P=0．037，P=0．031）。治疗后三组患者射血分数增高差异无统计学意义。结论瑞舒伐他汀在一定程度上可逆转Ⅲ度房室传导阻滞双腔起搏器置入患者心脏重构，改善心功能。
Objective To evaluate the effect of rosuvastatin on NT-proBNP and cardiac remodeling fol- lowing dual chamber pacemaker implantation in the patients with Ⅲ° atfioventficular block. Methods 60 Ⅲ° a- trioventricular block patients who received the dual chamber pacemaker implantation were selected in this study. They were divided into the control group （n=20）, rosuvastatin 5 mg group （n=20） and 10 mg group （n=20） ran- domly. NT-proBNP, LA diameter, LVEDD, LVESD and LVEF were measured at baseline and 12 months. Results Baseline data were similar between the three groups （P〉0.05）. Plasma NT-proBNP level decreased after 12 months of treatment in both pacemaker group and 10 mg group （P〈0.01）. NT-proBNP and LA were significantly reduced in 10rag group but not in control group （P=0.05, P=0.048）. There was no significant difference in LVEF among the three groups after operation. Conclusion Intensive statin therapy was effective for preventing ventficu- lar remodeling and improving cardiac function after dual-chamber-pacemaker implantation in SSS patients.
出处
《中国心血管病研究》
CAS
2013年第6期425-428,共4页
Chinese Journal of Cardiovascular Research
关键词
瑞舒伐他汀
心脏起搏器
利钠肽
脑
心动过缓
心室重构
Rosuvastatin
Artificial pacemaker
Natriuretic peptide, brain
Bradyarrhythmias
Ventricular remodeling
